The Relationship of Bone Mineral Density in Men with Chronic Obstructive Pulmonary Disease Classified According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Combined Chronic Obstructive Pulmonary Disease (COPD) Assessment System

Yoriko Sakurai-Iesato¹, Naoko Kawata¹, Yuji Tada¹, Ken Iesato¹, Yukiko Matsuura¹, Misuzu Yahaba¹, Toshio Suzuki¹, Jun Ikari¹, Noriyuki Yanagawa¹, Yasunori Kasahara¹, James West² and Koichiro Tatsumi¹

Abstract

Objective Osteoporosis, which is now recognized as a major comorbidity of chronic obstructive pulmonary disease (COPD), must be diagnosed by appropriate methods. The aims of this study were to clarify the relationships between bone mineral density (BMD) and COPD-related clinical variables and to explore the association of BMD with the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification in men.

Methods We enrolled 50 Japanese men with clinically stable COPD who underwent dual-energy X-ray absorptiometry (DEXA), pulmonary function testing, and computerized tomography (CT) and who had completed a questionnaire (COPD assessment test [CAT]). We determined the association between the T-score and other tested parameters and compared the BMD of patients in each GOLD category.

Results Twenty-three of the 50 patients (46.0%) were diagnosed with osteopenia, and 7 (14.0%) were diagnosed with osteoporosis. The BMD findings were significantly correlated with the CAT score, forced expiratory volume in 1 second percentage predicted (FEV₁% predicted), low attenuation volume percentage (LAV%), and percentage of cross-sectional area of small pulmonary vessels (%CSA) on CT images. Notably, the median T-score of the GOLD category D participants was significantly lower than that of the participants in each of the other categories (A [-0.98], B [-1.06], C [-1.05], and D [-2.19], p<0.05).

Conclusion Reduced BMD was associated with airflow limitation, extent of radiographic findings, and a poor quality of life (QOL) in patients with COPD. The BMD of GOLD category D patients was the lowest of all of the patients evaluated, and category D patients may benefit from active intervention for osteoporosis.

Key words: dual-energy X-ray absorptiometry (DEXA), bone mineral density (BMD), COPD assessment test (CAT), combined COPD assessment system

Introduction

Osteoporosis, which is now recognized as a major comorbidity of chronic obstructive pulmonary disease (COPD), must be diagnosed by appropriate methods and properly treated (1, 2). The prevalence of osteoporosis in patients with COPD ranges from 4% to as high as 59% (2). Osteo-
Based on the GOLD criteria (16). Information on medical COPD. The diagnosis and classification of COPD were to August 2013 for management of moderate to very severe who presented to Chiba University Hospital from May 2012.

**Study population**

This was a cross-sectional study that enrolled 50 men who presented to Chiba University Hospital from May 2012 to August 2013 for management of moderate to very severe COPD. The diagnosis and classification of COPD were based on the GOLD criteria (16). Information on medical history, smoking status, and corticosteroid use was obtained from patient interviews and medical records. Exacerbation of COPD was defined as worsening of the disease that required a short course of treatment with prednisolone (up to two weeks) alone or combined with an antibiotic, or immediate hospitalization because of COPD (9). All of these patients were clinically stable and had not developed an exacerbation at least four weeks prior to enrollment.

The comorbidities and treatments of the 50 participants were evaluated by a pulmonary physician. At the enrollment, patients were asked to state their comorbidities based on the Charlson Comorbidity Index. Furthermore, to ensure that no well-treated comorbidities were omitted, patients’ prescriptions were consulted. Patients’ medical records were also checked for ongoing contact with hospital departments other than the Department of Respiratory Medicine to reveal unnoticed, non-treated comorbidities.

We excluded the following patients: 1) those with obvious respiratory disease other than COPD; 2) those with any malignancy within the previous five years; 3) those with a history of bone disease; 4) those with a history of a metabolic, endocrine, or collagen disease or chronic renal failure that might affect bone loss; 5) those currently receiving oral systemic corticosteroid therapy; and 6) those receiving osteoporosis treatment, such as a bisphosphonate or vitamin D analogue.

The participants completed a CAT questionnaire at the time of recruitment. The CAT questionnaire covers eight items (cough, phlegm, chest tightness, breathlessness, activity limitation at home, confidence in leaving home, sleep, and energy) that are assigned scores by the patient.

The study patients were then classified according to the GOLD combined COPD assessment system as follows: category A (low risk, fewer symptoms), category B (low risk, more symptoms), category C (high risk, fewer symptoms) and category D (high risk, more symptoms) (16).

This study was approved by the ethics committee of the Chiba University School of Medicine (approval number: 857), and written informed consent was obtained from all study participants.

**Pulmonary function tests (PFTs)**

After inhaling a short-acting bronchodilator, each study patient underwent pulmonary function testing using a CHSTAC-8900 spirometer (Chest MI, Tokyo, Japan). PFTs were performed in accordance with the guidelines of the American Thoracic Society and European Respiratory Society (19). Total lung volume was determined using the helium dilution method, and the diffusing capacity for carbon monoxide (DLco) and alveolar ventilation (VA) were determined using the single breath method. The values for forced expiratory volume in 1 second percentage (FEV, %) predicted and percentage of DLco/VA (DLco/VA %) predicted were calculated using the equations of the Japanese Respiratory Society (20).
BMD measurements

BMD measurements were obtained by DEXA at the lumbar spine (L2-L4) and hip (total hip and femoral neck) using a Discovery A (SN82085) DEXA scanner (Hologic, Bedford, USA). The diagnoses of osteoporosis and osteopenia were based on the criteria of the World Health Organization (WHO) and each patient’s lowest T-score of three DEXA measurements. The WHO criteria for BMD are as follows: osteoporosis, T-score ≤−2.5 standard deviations (SD); osteopenia, T-score −2.5 SD and >−2.5 SD; and normal bone tissue, T-score ≥−2.5 SD below the average young adult mean (21). The 10-year probability of suffering major osteoporotic and hip fractures was calculated using the T-score and the Japanese version of the fracture risk assessment tool (FRAX®) (22).

Multi-detector computed tomography (MDCT) and CT measurements

All patients underwent MDCT, and the CT parameters were determined as previously reported (23, 24). All images were reconstructed using standard reconstruction algorithms, and the reconstructed images were transferred to a commercial workstation (Aze, Tokyo, Japan). Lung volumes with attenuation values of <−960 Hounsfield units (HU) were segmented as low attenuation volume (LAV). The proportion of LAV to whole lung volume was calculated as the LAV% (24).

The cross-sectional area of small pulmonary vessels (CSA) was measured as described previously (23). For CSA measurements, 3 lung images (upper, middle, and lower lung fields) were analyzed using the Image J software program, Version 1.44. CSA measurements were performed in accordance with the method of Matsuoka et al. (25, 26). The percentage of the total CSA for the lung area <5 mm² (%CSA<5) was calculated.

Statistical analyses

The results are shown as the means ± SD or the median (range). The univariate associations between the T-score and CAT scores, PFT results, and MDCT results were analyzed using Pearson’s correlation coefficient or Spearman’s rank correlation coefficient as appropriate. A multivariate regression analysis was also performed using the clinical variables to evaluate the independent determinants of the T-score. The comparison of the COPD categories (A-D) was performed using a one-way factorial analysis of variance for multiple comparisons of continuous variables using the Tukey-Kramer honest significant difference test. The chi-squared test was used for the comparison of categorical variables. The level of significance was set at p<0.05. All statistical analyses were performed using the JMP 10.0 software pro-

Table 1. Characteristics and Pulmonary Function Test Results of 50 Study Participants with COPD.

|                       | Total (n=50) | Stage II (n=23, 46.0%) | Stage III (n=18, 36.0%) | Stage IV (n=9, 18.0%) |
|-----------------------|-------------|------------------------|-------------------------|-----------------------|
| Age (years)           | 70.4 (7.3)  | 68.8 (8.1)             | 73.2 (5.6)              | 69.0 (6.5)            |
| BMI (kg/m²)           | 23.2 (3.4)  | 24.0 (3.3)             | 23.5 (3.5)              | 20.2 (3.6)            |
| Smoking history (pack-years) | 50.0 (12.5-150.0) | 44.5 (12.5-120.0) | 57.5 (14.0-150.0) | 70.5 (36.0-94.0) |
| Current-smoker, number (%) | 7 (14.0%)   | 5 (21.7%)              | 0 (0%)                  | 2 (22.2%)            |
| CAT score             | 10 (0-36)   | 9 (3-17)               | 8 (0-36)                | 23 (2-35)            |
| FRAX® (major osteoporotic/hip fracture) (%) | 5.5 (2.5-13.0) | 5.1 (2.5-9.1) | 5.8 (3.0-13.0) | 7.8 (4.1-12.0) |
| VC% predicted (%)     | 88.9 (16.2) | 96.3 (11.8)            | 86.7 (16.4)             | 74.5 (14.1)          |
| FVC (L)               | 3.01 (0.70) | 3.34 (0.61)            | 2.89 (0.66)             | 2.43 (0.55)          |
| FVC% predicted (%)    | 85.8 (17.3) | 95.3 (11.9)            | 83.2 (15.9)             | 66.9 (13.7)          |
| FEV₁(FVC)             | 1.42 (0.51) | 1.85 (0.32)            | 1.22 (0.25)             | 0.72 (0.13)          |
| FEV₁/FVC (%)          | 46.8 (12.0) | 56.1 (7.0)             | 43.4 (8.3)              | 30.0 (3.3)           |
| FEV₁% predicted (%)   | 50.4 (17.0) | 65.4 (7.7)             | 44.1 (7.6)              | 24.3 (3.2)           |
| DLco/VAs predicted (%)| 69.9 (29.4) | 79.3 (24.5)            | 74.4 (28.5)             | 41.3 (22.6)          |
| RV/TLC (%)            | 46.2 (8.4)  | 41.5 (5.2)             | 47.5 (6.8)              | 55.6 (7.5)           |
| LAV (%)               | 6.5 (0.1-51.1) | 2.2 (0.3-32.8) | 8.6 (0.2-25.8) | 25.9 (0.1-51.1) |
| %CSA<5 (number %)     | 0.74 (0.19) | 0.77 (0.17)            | 0.76 (0.19)             | 0.58 (0.16)          |
| GOLD category A/B/C/D, number (%) | 12 (24.0%)/11 (22.0%)/11 (22.0%)/16 (32.0%) | 38 (76.0%)/12 (22.0%)/1 (2.0%) |
| Exacerbation history (0/1±2 exacerbations per year), number (%) | 12 (24.0%)/11 (22.0%)/11 (22.0%)/16 (32.0%) | 38 (76.0%)/12 (22.0%)/1 (2.0%) |
Table 2. Comorbidities and Treatments of 50 Participants with COPD.

| Comorbidity                          | n (%)  |
|--------------------------------------|--------|
| Cardiovascular disease               | 7 (14.0%) |
| Ischemic heart disease               | 3 (6.0%) |
| Atrial fibrillation                  | 3 (6.0%) |
| Post aortic valve replacement        | 1 (2.0%) |
| Hypertension                         | 25 (50.0%) |
| Diabetes                             | 4 (8.0%) |
| Dyslipidemia                         | 13 (26.0%) |
| Hyperuricemia                        | 3 (6.0%) |
| Gastroesophageal reflux disease      | 12 (24.0%) |
| Depression/Anxiety                   | 1 (2.0%)/1 (2.0%) |

| COPD treatment, oral steroid use and warfarin use | n (%)  |
|--------------------------------------------------|--------|
| Inhaled therapy                                  |        |
| Long-acting muscarinic antagonist (LAMA)          | 12 (24.0%) |
| Long acting β2-agonist (LABA)                    | 2 (4.0%) |
| Inhaled corticosteroid (ICS)                     | 0 (0%)  |
| LAMA/LABA                                         | 2 (4.0%) |
| ICS/LAMA                                          | 1 (2.0%) |
| ICS/LABA                                          | 9 (18.0%) |
| ICS/LAMA/LABA                                     | 13 (26.0%) |
| Carbocisteine                                     | 14 (28.0%) |
| Theophylline                                      | 15 (30.0%) |
| Oral and/or intravenous corticosteroid use        | 0 (0%)  |
| Long-term oxygen therapy                          | 4 (8.0%) |
| Warfarin                                          | 4 (8.0%) |

COPD: chronic obstructive pulmonary disease, ICS: inhaled corticosteroid, LABA: long acting β2-agonist, LAMA: long-acting muscarinic antagonist

gram (SAS Institute, Cary, USA).

Results

Characteristics of participants

The demographics, CAT scores, FRAX® scores, and PFT results of the study patients are summarized in Table 1. All participants were male and had a history of smoking. The median CAT score was 10. The mean age, and values for FEV1/FVC, and FEV1% predicted were 70.4 years, 46.8%, and 50.4%, respectively. The number of patients in each GOLD stage were as follows: stage II, n=23; stage III, n=18; and stage IV, n=9; and the number of patients in each GOLD category were: category A, n=12; category B, n=11; category C, n=11 and category D, n=16. Eleven patients and 1 patient experienced an acute exacerbation once and twice per year prior to their enrollment, respectively. These patients had been treated by antibiotics alone.

The prevalence of comorbidities is shown in Table 2. Half of our 50 patients had hypertension, 13 (26.0%) had dyslipidemia, and 7 (14.0%) had cardiovascular disease. The number of patients treated for COPD with a long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA), LAMA/LABA, inhaled corticosteroids (ICS)/LAMA, ICS/LABA, and ICS/LAMA/LABA were 12 (24.0%), 2 (4.0%), 2 (4.0%), 1 (2.0%), 9 (18.0%), and 13 (26.0%), respectively. The number of patients treated with oral and/or intravenous corticosteroids, long-term oxygen therapy, and warfarin were 0 (0%), 4 (8.0%), and 4 (8.0%), respectively.

BMD assessed by DEXA

The lumbar vertebrae and proximal femur (total hip or neck) were the locations of the lowest T-score in 12 (24.0%) and 38 (76.0%) participants, respectively. Table 3 shows the T-scores according to the GOLD stage. Twenty-three of 50 patients (46.0%) were diagnosed with osteopenia, and 7 (14.0%) were diagnosed with osteoporosis. Low BMD (osteopenia + osteoporosis) was present in 47.8% of GOLD stage II (n=11), 55.6% of GOLD stage III (n=10), and 100% of GOLD stage IV patients (n=9), respectively. Twenty-three of our 50 patients (46.0%) were treated by ICS (Table 2). The difference in the T-scores between ICS users and non-users was not significant (-1.70 vs. -1.14, p=0.052; Fig. 1). The number of patients treated by ICS in each GOLD category were as follows: category A (n=4, 33.3%), B (n=4, 36.4%), C (n=3, 27.3%), and D (n=12, 75.0%). On an intra-category comparison, there was no statistically significant difference in the T-scores between ICS users and non-users (data not shown).
The T-scores were positively correlated with FEV1/FVC (r=0.37, p<0.01; Fig. 3a). The scores for activities and sleep tended to be negatively correlated with the T-scores (Fig. 2b-d, respectively). The scores for chest tightness (r=-0.32, p=0.02), breathlessness (r=-0.36, p<0.01), and confidence leaving home (r=-0.37, p<0.01) were significantly correlated with the T-scores (Fig. 2a). Of the 8 CAT questions, the scores for confidence leaving home (r=-0.37, p<0.01) were negatively correlated with the T-scores (Fig. 2d). A multivariate regression analysis showed that only FEV1% predicted value was an independent predictive factor of the T-score (β=0.51, p=0.0001; Table 4).

**Table 3. Bone Mineral Density of 50 Participants with COPD Stratified according to GOLD Stage.**

| GOLD Stage | n | T-score mean (SD) | T-score range (SD) | Osteopenia n (%) | Osteoporosis n (%) |
|------------|---|------------------|-------------------|-----------------|------------------|
| II         | 23| -1.02 (-2.3)     | -1.0 - 1.1        | 11 (47.8%)      | 0 (0%)           |
| III        | 18| -1.27 (-3.2)     | -0.7 - 0.7        | 7 (38.9%)       | 3 (16.7%)        |
| IV         | 9 | -2.62 (-4.7)     | -1.3 - 0.5        | 5 (55.6%)       | 4 (44.4%)        |
| Total      | 50| -1.40 (-4.7)     | -1.0 - 1.0        | 23 (46.0%)      | 7 (14.0%)        |

Osteopenia: T-score = 1.0 SD and >-2.5 SD, Osteoporosis: T-score ≤-2.5 SD.

COPD: chronic obstructive pulmonary disease, GOLD: Global Initiative for Chronic Obstructive Lung Disease, SD: standard deviation

**Table 4. Univariate Analysis between T-score and Clinical Variables and Stepwise Multivariate Analysis Showing the Relative Contribution of Each Variable to Determine T-score.**

| Variable                  | Univariate | Multivariate |
|---------------------------|------------|--------------|
| Age (years)               | r: -0.19   | p: 0.18      |
| BMI (kg/m²)               | r: 0.37    | p<0.01       |
| Smoking history (pack-years) | r: -0.01 | 0.92        |
| CAT score                 | r: 0.31    | p: 0.03      |
| FEV₁% predicted (%)      | r: 0.51    | p<0.001      |
| DLco/VA predicted (%)    | r: 0.17    | p: 0.33      |
| RV/TLC (%)               | r: -0.46   | p<0.01       |
| LAV (%)                  | r: -0.34   | 0.02        |
| %CSA<5 (%)               | r: 0.36    | p<0.01       |

BMI: body mass index, CAT: chronic obstructive pulmonary disease assessment test, COPD: chronic obstructive pulmonary disease, FEV₁% predicted: percentage of FEV₁ predicted values, RV/TLC: ratio of residual volume to total lung capacity, DLco/VA predicted: percentage of diffusing capacity of carbon monoxide/alveolar ventilation predicted value, LAV: percentage of low attenuation volume, %CSA<5: percentage of cross-sectional area of small pulmonary vessels less than 5 mm², SD: standard deviation

**Association between BMD and CAT Score, PFT, and CT findings**

The association between the BMD and clinical variables is summarized in Table 4. There was a significant negative correlation between the T-scores and CAT scores (r=-0.31, p=0.03; Fig. 2a). Of the 8 CAT questions, the scores for chest tightness (r=-0.32, p=0.02), breathlessness (r=-0.36, p=0.01), and confidence leaving home (r=-0.37, p<0.01) were significantly correlated with the T-scores (Fig. 2b-d, respectively). The scores for activities and sleep tended to be negatively correlated with BMD, although the correlations were not statistically significant (data not shown).

The BMD findings were significantly positively correlated with the body mass index (BMI) (r=0.37, p<0.01; Fig. 3a). The T-scores were positively correlated with FEV₁/FVC (r=0.51, p<0.001; data not shown) and FEV₁% predicted values (r=0.51, p<0.001; Fig. 3b), negatively correlated with the severity of emphysema (LAV%) (r=-0.34, p=0.02; Fig. 3c), and positively correlated with %CSA<5 (r=0.36, p<0.01; Fig. 3d). A multivariate regression analysis showed that only FEV₁% predicted value was an independent predictive factor of the T-score (β=0.51, p=0.0001; Table 4).

**BMD of participants in each GOLD COPD category**

The median T-scores of the participants in each GOLD category were as follows: category A (-0.98), B (-1.06), C (-1.05), and D (-2.19) (Table 5). The median T-score of participants in category D was significantly lower than the median scores of each of the other categories (Fig. 4). There was a significant difference in the T-scores between patients classified according to severe or very severe airflow limitation but not between patients classified according to mild or moderate airflow limitation with the same degree of airflow limitation and rate of exacerbation.

**Discussion**

The key findings of this study were as follows: first, the BMD of our male participants with COPD was significantly associated with the CAT score, degree of obstructive impairment, and radiological parameters; second, and more importantly, a reduced BMD was associated with a complex of...
deteriorated quality of life (QOL), the severity of obstructive impairment, and the exacerbation rate. We found that the BMD of GOLD category D patients was the lowest of all the patients evaluated.

The recent GOLD assessment system for the severity of COPD was updated on the basis of not only the extent of airflow limitation but also the symptoms of the patient (16). In particular, treatment planning now emphasizes the patient’s QOL. Previous studies found significant associations between osteoporosis and higher CAT scores and/or higher mMRC-grade dyspnea (15, 27). We similarly found that a reduced BMD of patients (osteoporosis and osteopenia) was associated with higher CAT scores (worse QOL). Additionally, we found that three of the eight CAT items (‘chest tightness’, ‘breathlessness’, and ‘confidence in leaving home’) were correlated with a low BMD. We postulated that COPD patients who are less confident in leaving home are those who feel tightness in the chest and become short of breath when walking uphill or climbing stairs, which leads to physical inactivity, and over time, a decreased BMD. These findings are consistent with the knowledge that patients with serious breathing problems are prone to a sedentary or very inactive lifestyle, which leads to musculoskeletal dysfunction and a poor outcome (28, 29). Low BMD tends to increase the risk of fragility fractures (27) and may be associated with acute exacerbation of COPD (9, 30).

Regarding the GOLD combined COPD assessment system (16), we found that the BMD was obviously reduced in category D patients (high risk, more symptoms). Although the BMD of our study patients was weakly but significantly correlated with CAT scores and the degree of obstructive impairment, the BMD of the patients in GOLD category D was significantly lower than in the other three GOLD categories.

A variety of risk factors such as smoking status, age, BMI, and oral systemic corticosteroid therapy are associated with low BMD (21). Dyspnea on exertion results in decreased daily activity. Additionally, a loss of appetite and malnutrition (calcium and vitamin D deficiency) lead to muscle atrophy and physical dysfunction. These factors lead to osteoporosis in COPD patients. Furthermore, systemic inflammation plays a major role in the development of osteoporosis in COPD (31, 32). Inflammatory cytokines activate the expression of receptor activator of nuclear factor-κB ligand (RANKL), resulting in RANKL-mediated bone resorption. Exacerbation of COPD reduces the activities of daily living and pulmonary function, worsening the prognosis and affecting the bone density. Therefore, category D patients, whose symptoms and airflow limitation were severe and/or whose acute exacerbations were frequent, developed decreased bone density compared with other patients. As such, assignment to the GOLD category D might be an indi-

![Figure 2. Correlations between BMD T-scores and CAT. There was a significant negative correlation between the T-scores and (a) CAT scores (r=-0.31, p=0.03). Among 8 questions, scores for (b) ‘chest tightness,’ (c) ‘breathlessness,’ and (d) ‘confidence in leaving home’ were significantly correlated with T-scores (r=-0.32, p=0.02, r=-0.36, p=0.01, and r=-0.37, p<0.01, respectively). BMD: bone mineral density, CAT: chronic obstructive pulmonary disease assessment test, SD: standard deviations.](image-url)
Figure 3. Correlations between BMD T-scores and other parameters. The T-scores were significantly positively correlated with (a) BMI values ($r=0.37, p<0.01$), (b) FEV$_1$% predicted values ($r=0.51, p<0.001$), and (d) %CSA<5 values ($r=0.36, p<0.01$). A significant negative correlation was found between T-scores and (c) LAV% values ($r=-0.34, p=0.02$).

Table 5. Bone Mineral Density of 50 Participants with COPD Stratified according to GOLD Category.

| Category | n | T-score mean (SD) | T-score range (SD) | Osteopenia n (%) | Osteoporosis n (%) |
|----------|---|------------------|--------------------|------------------|-------------------|
| A        | 12 | -0.98 (-2.3)     | -1.0               | 5 (41.7)         | 0 (0%)            |
| B        | 11 | -1.06 (-2.3)     | -1.0               | 6 (54.5%)        | 0 (0%)            |
| C        | 11 | -1.05 (-2.8)     | -0.7               | 4 (36.4%)        | 1 (9.1%)          |
| D        | 16 | -2.19 (-4.7)     | -0.4               | 8 (50.0%)        | 6 (37.5%)         |
| Total    | 50 | -1.40 (-4.7)     | -1.0               | 23 (46.0%)       | 7 (14.0%)         |

Osteopenia: T-score < -1.0 SD and > -2.5 SD. Osteoporosis: T-score ≤ -2.5 SD.

We found a high prevalence of osteopenia (46.0%) and might determine the difference between a CAT score <10 versus ≥10 in patients with mild or moderate airflow limitation (33). A recent cohort study found that the survival rate of category C patients was better than that of category B patients (34). Worsening symptoms and severe or more severe airflow limitations induce physical inactivity, which may contribute to musculoskeletal disorders (35). Even with severe disease, category C patients may be more active if they are less symptomatic, which would mitigate the bone loss caused by physical disuse.
osteoporosis (14.0%) in our study cohort. The prevalence of bone loss was slightly higher in this study than in another study of Japanese men (27, 36), probably due to the mean severity of air flow imitation. In our study, 23 patients (46.0%) were using ICS as a treatment for COPD. Although the relationship between BMD and the use of ICS is unclear, a recent meta-analysis of randomized controlled trials and observational studies found that long-term exposure to ICS (fluticasone and budesonide) was significantly associated with an increased likelihood of fractures among patients with COPD (37). In contrast, the Towards a Revolution in COPD Health (TORCH) study found that the effect of inhaled fluticasone on bone was not significant (38). Long-term budesonide treatment also had no clinically significant effect on BMD or fractures (39). The effect of ICS on osteoporosis in COPD remains uncertain, and additional studies on the association between the long-term use of ICS and BMD are needed.

Osteoporotic fractures, such as vertebral and rib cage fractures, lead to pain and rib cage deformities (3), which lead to exertional dyspnea, inactivity, impaired expectoration of sputum, a decline in the lung function, followed by exacerbation of COPD, and pneumonia (1). The prevalence of vertebral fractures in 2,981 COPD patients in the Evaluation of Obstructive Lung disease and Osteoporosis (EOLO) study was 41.5% (40). The majority of our COPD patients had lower T-scores of the proximal femur (total hip or neck) than of the vertebrae, which is consistent with previous reports from Western countries (10, 41). This finding suggests that DEXA assessment of the hips of COPD patients is important for preventing fragility fractures. Many COPD patients have quadriceps weakness (42). Vertebral and hip fractures have a marked impact on patients’ activities of daily living, outcomes, and clinical costs (43, 44). Thus, monitoring BMD by DEXA is expected to be beneficial for COPD patients.

Previous studies have used CT to establish a relationship between BMD (mainly of the vertebrae) and airflow limitation and percentage of low attenuation area (LAA%) (8, 45). In addition, we found a correlation between BMD and %CSA <5, a novel CT marker for expressing the area of small pulmonary vessels. %CSA <5 has been shown to correlate with radiographic emphysema as well as with pulmonary hypertension and aortic atherosclerosis associated with COPD (25, 46). %CSA <5 may reflect the degree of vascular inflammation, and COPD was recently recognized to be a systemic inflammatory disease (47, 48). Alveolar destruction, loss of pulmonary endothelium, and loss of bone matrix due to activated osteoclasts might have common mechanisms of action, including the hypersecretion of inflammatory cytokines such as interleukin-6, interleukin-1β, and tumor necrosis factor-α (48, 49).

Study limitations

This study has several limitations. First, the number of participants was relatively small, and no control participants without COPD or with mild COPD were enrolled. Second, this study was conducted at a single facility and recruited COPD participants via medical checkups performed in the area served by our hospital, which may have involved referral filter bias. This bias may explain why there were no GOLD Stage I participants or participants with vertebral fractures or kyphosis, as in other studies (27). Third, we did not perform X-rays of the thoracolumbar spine. Pulmonary physicians should be aware of the high prevalence of vertebral body osteoporotic fractures in COPD patients, and DEXA and spinal X-rays should be performed (43). Finally, we only evaluated the BMD, not the bone quality or fat-free mass (50, 51). These factors actually determine the risk of falls and femoral fractures that directly affect a patient’s QOL.

Conclusion

The results of our study suggest that a reduced BMD is closely associated with disease severity and an impaired QOL in patients with COPD. Based on our data, a GOLD category D assessment may be an appropriate indication for a diagnostic assessment of BMD and active treatment for low BMD. Future studies should focus on the accurate identification of those COPD patients who will benefit most by early treatment for osteoporosis.

Author’s disclosure of potential Conflicts of Interest (COI).
Koichiro Tatsumi: Honoraria, GlaxoSmithKline and Pfizer.

Financial support
Dr. Tatsumi was supported by a grant to the Respiratory Failure Research Group from the Ministry of Health, Labor and Welfare of Japan (No 21590962). The funders had no role in study design, data collection and analysis, decision to publish, or
References

1. Lehouck A, Boonen S, Declerck M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest 139: 648-657, 2011.
2. Graat-Verboom L, Wouters EF, Smeek FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 34: 209-218, 2009.
3. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 141: 68-71, 1990.
4. Carter JD, Patel S, Sultan FL, et al. The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102: 1165-1172, 2008.
5. Regan EA, Radcliff TA, Henderson WG, et al. Improving hip fractures outcomes for COPD patients. COPD 10: 11-19, 2013.
6. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114: 10-14, 2003.
7. KJensl A, Mowinckel P, Ryg MS, Falch JA. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 40: 493-497, 2007.
8. Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary embolism and osteoporosis assessed by CT in patients with COPD. Chest 134: 1244-1249, 2008.
9. Kiyokawa H, Muro S, Oguma T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD 9: 235-242, 2012.
10. Duckers JM, Evans BA, Fraser WD, Stone MD, Bolton CE, Shale DJ. Low bone mineral density in men with chronic obstructive pulmonary disease. Respir Res 12: 101, 2011.
11. Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Conner E. Osteoporotic Fractures in Men (MoFOS) Research Group. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 21: 1341-1349, 2010.
12. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 34: 648-654, 2009.
13. Jones PW, Harding G, Wiklund I, et al. Tests of the responsive-ness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 142: 134-140, 2012.
14. Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 66: 425-429, 2011.
15. Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 15: 13, 2014.
16. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365, 2013.
17. Ryan CS, Perkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 22: 1845-1853, 2011.
18. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 358: 1474-1482, 2008.
19. American Thoracic Society European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Version 1.2. New York: American Thoracic Society; 2004 [updated 2005 September 8] [cited 2016 May 20]. Available from: http://www.thoracic.org/go/copd
20. Committee of Pulmonary Physiology, the Japanese Respiratory Society. Guidelines for pulmonary function tests: spirometry, flow-volume curve, diffusion capacity of the lung. 1st ed. Medical Review Co., Ltd., Tokyo, 2004 (in Japanese).
21. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4: 368-381, 1994.
22. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK [cited 2016 May 20]. Available from: https://www.shef.ac.uk/FRAX/index.aspx
23. Matsuura Y, Kawata N, Yanagawa N, et al. Quantitative assessment of cross-sectional area of small pulmonary vessels in patients with COPD using inspiratory and expiratory MDCT. Eur J Radiol 82: 1804-1810, 2013.
24. Yanagawa N, Kawata N, Matsuura Y, et al. Effect of threshold on the correlation between airflow obstruction and low attenuation volume in smokers assessed by inspiratory and expiratory MDCT. Acta Radiol 56: 438-446, 2015.
25. Matsuoka S, Washko GR, Yamashiro T, et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 181: 218-225, 2010.
26. Matsuoka S, Washko GR, Dransfield MT, et al. Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol 17: 93-99, 2010.
27. Ogura-Tomomatsu H, Asano K, Tomomatsu K, et al. Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD 9: 332-337, 2012.
28. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121: 1434-1440, 2002.
29. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 140: 331-342, 2011.
30. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138, 2010.
31. Zhang PF, Pan L, Luo YZ, Zhao HJ, Cai SX. Interrelation of circulating matrix metalloproteinase-9, TNF-alpha, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. COPD 10: 650-656, 2013.
32. Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res 12: 157, 2011.
33. Agusti A, Hurd S, Jones P, et al. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 42: 1391-1401, 2013.
34. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 186: 975-981, 2012.
35. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with COPD. Am J Respir Crit Care Med 192: 295-306, 2015.
36. Watanabe R, Tanaka T, Aita K, et al. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 33: 392-400, 2015.
37. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66: 699-708, 2011.
38. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 136: 1456-1465, 2009.
39. Johnell O, Pauwels R, Loladahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 19: 1058-1063, 2002.
40. Nuti R, Siviero P, Maggi S, et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the ELOO Study. Osteoporos Int 20: 989-998, 2009.

41. Graat-Verboom L, Smeenk FW, van den Borne BE, et al. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med 106: 861-870, 2012.

42. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 36: 81-88, 2010.

43. Graat-Verboom L, van den Borne BE, Smeenk FW, Spruit MA, Wouters EF. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res 26: 561-568, 2011.

44. Myers AH, Robinson EG, Van Natta ML, Michelson JD, Collins K, Baker SP. Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol 134: 1128-1137, 1991.

45. Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res 28: 1369-1377, 2013.

46. Matsuoka S, Yamashiro T, Díaz A, et al. The relationship between small pulmonary vascular alteration and aortic atherosclerosis in chronic obstructive pulmonary disease: quantitative CT analysis. Acad Radiol 18: 40-46, 2011.

47. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 107: 1376-1384, 2013.

48. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185, 2009.

49. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 1259-1265, 2007.

50. Teopompi E, Tzani P, Aiello M, et al. Fat-free mass depletion is associated with poor exercise capacity irrespective of dynamic hyperinflation in COPD patients. Respir Care 59: 718-725, 2014.

51. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 1286-1293, 2004.